Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
133.85(c) 134.7(c) 135.2(c) 137.4(c) 136.65(c) Last
692 313 632 469 393 007 583 582 405 162 Volume
+0.34% +0.64% +0.37% +1.63% -0.55% Change
More quotes
Financials
Sales 2020 17 377 M 21 061 M 21 061 M
Net income 2020 2 010 M 2 436 M 2 436 M
Net Debt 2020 11 224 M 13 604 M 13 604 M
P/E ratio 2020 29,3x
Yield 2020 1,03%
Sales 2021 18 225 M 22 088 M 22 088 M
Net income 2021 2 162 M 2 621 M 2 621 M
Net Debt 2021 9 362 M 11 347 M 11 347 M
P/E ratio 2021 26,9x
Yield 2021 1,07%
Capitalization 59 412 M 72 102 M 72 008 M
EV / Sales 2020 4,06x
EV / Sales 2021 3,77x
Nbr of Employees 58 077
Free-Float 29,7%
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - pharmaceutical products (41.6%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - solutions and products for scientific and biotechnological research... 
Sector
Pharmaceuticals
Calendar
01/11Presentation
More about the company
Notations Surperformance© of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
All news about MERCK KGAA
05:41aARIX BIOSCIENCE : Artios and Merck KGaA announce global strategic collaboration
AQ
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
12/03MERCK : Enters Research Agreement With Artios on Precision Oncology Treatments
DJ
12/01MERCK : to Accelerate Commercialization of OLED Display Materials Through Partne..
DJ
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
MD
11/26MERCK : Partners With Siemens on New Plant
DJ
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
11/16MERCK KGAA : JP Morgan remains Neutral
MD
More news
News in other languages on MERCK KGAA
12/03NACH MILLIARDEN-KAUF : Merck sieht sich bei Halbleitern auf Kurs
12/03MERCK : vereinbart milliardenschwere Krebs-Partnerschaft
12/03MERCK : und Artios Pharma kooperieren im Bereich DNA-Reparaturmechanismen
12/01MERCK : schließt Partnerschaften für Materialien für flexible OLED-Displays
11/30MERCK KGAA : Kepler Cheuvreux maintient sa recommandation à l'achat
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | MarketScreener
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,14 €
Last Close Price 136,65 €
Spread / Highest target 23,7%
Spread / Average Target -1,10%
Spread / Lowest Target -26,1%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA29.71%72 586
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD109.20%20 668
KYOWA KIRIN CO., LTD.11.47%14 828
BETTA PHARMACEUTICALS CO., LTD.49.24%5 986
YUHAN CORPORATION37.63%3 565
RECIPHARM AB (PUBL)29.29%2 026